株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国における神経刺激装置市場

U.S. Neurostimulation Devices Market

発行 Medtech Insight 商品コード 268428
出版日 ページ情報 英文 277 Pages, 67 Exhibits
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
米国における神経刺激装置市場 U.S. Neurostimulation Devices Market
出版日: 2015年06月30日 ページ情報: 英文 277 Pages, 67 Exhibits
概要

米国の埋め込み型神経刺激装置市場は、2014年に約23億米ドルに達しました。長引く経済の不安定性および財務的制約にも関わらず、同市場は大幅な技術進歩を遂げています。

当レポートでは、米国の植込み型神経刺激装置市場について調査し、主な製品、市場の現況/予測、罹患率、競合企業、サプライヤー別の市場シェア、および市場機会などを分析しています。

エグゼクティブサマリー

第1章 神経刺激技術の概要

  • 埋め込み型神経刺激装置
  • 非侵襲性末梢神経刺激
  • 経皮電気的神経刺激
  • クローズドループ刺激
  • 舌下神経刺激
  • 経皮的磁気刺激
  • 外部三叉神経刺激

第2章 神経刺激装置

  • アルツハイマー病
  • 多動症候群/多動性障害
  • 失明
  • 慢性うつ病
  • 慢性心不全
  • 慢性片頭痛
  • 慢性痛
  • ジストニア・本態性振戦・パーキンソン病
  • てんかん
  • 下垂足
  • 胃食道逆流
  • 胃不全まひ
  • 難聴
  • 失禁
  • 肥満
  • 強迫神経症
  • 睡眠時無呼吸
  • 脊髄損傷/まひ症
  • 脳卒中
  • 耳鳴り

第3章 埋め込み型神経刺激装置市場

  • 市場予測
  • 競合分析
    • 市場シェア
  • 新しい神経刺激技術
    • Nevro Corp.
    • Stimwave
    • 末梢神経刺激
      • Bioness
      • Autonomic Technologies, Inc.

付録A:企業リスト

付録B:参考資料

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: A594

An estimated 200 million people in the United States (U.S.) experience some degree of neurological impairment over the course of a lifetime. Among the many neurological disorders are chronic pain (including migraine headache), epilepsy, hearing loss, incontinence, major depression, Parkinson's disease, sleep apnea, and visual impairment/blindness. Typically, the initial treatment option for these conditions is standard pharmacotherapy or surgery; however, neurostimulation is gaining in popularity as a viable alternative among many people in the U.S. and worldwide. The estimated number of neurostimulation implant procedures has more than doubled over the past decade, reaching more than 1 million worldwide.

Implantable neurostimulation systems typically consist of three implantable components (the extension, lead, and power source) and two external components (the control magnet and a handheld programmer). The extension is used to connect the lead to the power source, and the lead is used to deliver the electrical stimulation to the targeted nerve(s).

For the purposes of this report, the total U.S. market for implantable neurostimulation devices includes sales derived from systems for 8 therapy segments, including the 5 core, established areas of deep brain stimulation (DBS), gastric nerve stimulation (GNS), spinal cord stimulation (SCS), sacral nerve stimulation (SNS), and vagus nerve stimulation (VNS), as well as neural prostheses (cochlear and recently launched retinal implants) and newly FDA-approved Vagal Blocking (VBLOC) therapy, for the treatment of obesity.

The large and burgeoning market for implantable neurostimulation devices in the U.S. has reached nearly $2.3 billion in 2014. Despite the lingering economic uncertainty and financial constraints that have affected many other medical device markets, this market is undergoing significant technological advancement due to heavy R&D and investment efforts by dozens of startups and leading medical device companies. The market is expected to experience high single-digit growth over the next half-decade, with many industry experts expecting its value to rival the multibillion-dollar markets for implantable defibrillators and coronary stents. A major reason for such optimism is not only the products' clinical and commercial success thus far, but also the need for more effective treatments for the large population of patients who suffer from debilitating, chronic, incurable conditions that require the long-term management of symptoms.

This dynamic, new report from Medtech Insight includes analyses of dozens of selected products, current/forecast markets (from 2014-2019), disease prevalence, competitors, market share by supplier, and opportunities in the U.S. Neurostimulation Devices Market. Specifically, this report covers leading and emerging implantable neurostimulation devices and next-generation technologies, as well as increasingly competitive less invasive or nonsurgical therapies, such as transcutaneous electrical nerve stimulation (TENS), peripheral nerve stimulation (PNS), transcutaneous magnetic stimulation (TMS), and external trigeminal nerve stimulation (eTNS).

Table of Contents

EXECUTIVE SUMMARY

  • i. Implantable Neurostimulation Devices Market
  • ii. Methodology
  • Exhibit ES-1: Estimated U.S. Prevalence of Selected Neurological Conditions
  • Exhibit ES-2: 2014, Implantable Neurostimulation Devices Market,. Estimated Percentage of Sales, by Type of Therapy
  • Exhibit ES-3: 2015, Leading Competitors and Products in the Implantable Neurostimulation Devices Market

1. NEUROSTIMULATION TECHNOLOGIES OVERVIEW

  • 1.1. Implantable Neurostimulators
    • 1.1.1. Deep Brain Stimulators
    • 1.1.2. Gastric Nerve Stimulators
    • 1.1.3. Sacral Nerve Stimulators
    • 1.1.4. Spinal Cord Stimulators
    • 1.1.5. Vagus Nerve Stimulators
    • 1.1.6. Vagal Blocking for Obesity
    • 1.1.7. Cochlear Implants
    • 1.1.8. Retinal Implants
  • 1.2. Noninvasive Peripheral Nerve Stimulation
  • 1.3. Transcutaneous Electrical Nerve Stimulation
  • 1.4. Closed-Loop Stimulation
  • 1.5. Hypoglossal Nerve Stimulation
  • 1.6. Transcutaneous Magnetic Stimulation
  • 1.7. External Trigeminal Nerve Stimulation
  • Exhibit 1-1: Estimated U.S. Prevalence of Selected Neurological Conditions
  • Exhibit 1-2: Selected Advantages and Disadvantages. of Neurostimulation Therapy
  • Exhibit 1-3: Estimated Number of Neurostimulation Implants,. by Selected Neurological Condition
  • Exhibit 1-4: Schematic Illustration of Deep Brain Stimulation

2. NEUROSTIMULATION DEVICES

  • 2.1.1. Alzheimer's Disease
    • 2.1.1.1. Beijing Pins Medical Co., Ltd.
    • 2.1.1.2. The Magstim Company
    • 2.1.1.3. Functional Neuromodulation Ltd.
  • 2.1.2. Attention-Deficit/Hyperactivity Disorder
    • 2.1.2.1. Brainsway
    • 2.1.2.2. NeuroSigma
    • 2.1.3. Autism
    • 2.1.3.1. Brainsway
    • 2.1.3.2. MagVenture A/S
  • 2.1.4. Blindness
    • 2.1.4.1. Bionic Vision Australia
    • 2.1.4.2. Pixium Vision
    • 2.1.4.3. Retina Implant AG
    • 2.1.4.4. Second Sight Medical Products
  • 2.1.5. Chronic Depression
    • 2.1.5.1. Brainsway Ltd.
    • 2.1.5.2. Cyberonics/Sorin Group
    • 2.1.5.3. Fisher Wallace
    • 2.1.5.4. MagVenture A/S
    • 2.1.5.5. Medtronic
    • 2.1.5.6. Neuronetics
    • 2.1.5.7. NeuroSigma
    • 2.1.5.8. St. Jude Medical
    • 2.1.5.9. Others
  • 2.1.6. Chronic Heart Failure
    • 2.1.6.1. BioControl Medical
    • 2.1.6.2. Cyberonics/Sorin Group
    • 2.1.6.3. Medtronic
    • 2.1.6.4. St. Jude Medical
  • 2.1.7. Chronic Migraine Headache
    • 2.1.7.1. Boston Scientific
    • 2.1.7.2. Medtronic
    • 2.1.7.3. St. Jude Medical
    • 2.1.7.4. Others (Cluster Headache/Migraine)
      • 2.1.7.4.1 Autonomic Technologies,. Inc.
      • 2.1.7.4.2 ElectroCore, LLC
  • 2.1.8. Chronic Pain
    • 2.1.8.1. Boston Scientific
    • 2.1.8.2. Medtronic
    • 2.1.8.3. St. Jude Medical
      • 2.1.8.3.1 Spinal Modulation/St. Jude Medical
      • 2.1.8.3.2 Neurotherm/St. Jude Medical
    • 2.1.8.4. Others
      • 2.1.8.4.1 Bioness, Inc.
      • 2.1.8.4.2 Mainstay Medical
      • 2.1.8.4.3 NeuroMetrix
      • 2.1.8.4.4 Neuros Medical
      • 2.1.8.4.5 Nevro Corp.
      • 2.1.8.4.6 Saluda Medical
      • 2.1.8.4.7 SPR Therapeutics
      • 2.1.8.4.8 Stimwave Technologies, Inc.
  • 2.1.9. Dystonia, Essential Tremor, and Parkinson's Disease
    • 2.1.9.1. Boston Scientific
    • 2.1.9.2. Medtronic
    • 2.1.9.3. St. Jude Medical
  • 2.1.10. Epilepsy
    • 2.1.10.1. Beijing Pins Medical Co., Ltd
    • 2.1.10.2. Cerbomed GmbH
    • 2.1.10.3. CerebralRx/BioControl Medical
    • 2.1.10.4. Cyberonics/Sorin Group
    • 2.1.10.5. Electrical Geodesics, Inc.
    • 2.1.10.6. Medtronic plc
    • 2.1.10.7. NeuroPace
    • 2.1.10.8. NeuroSigma
    • 2.1.10.9. NeuroVista/Cyberonics
  • 2.1.11. Foot Drop
    • 2.1.11.1. Bioness, Inc.
  • 2.1.12. Gastro-Esophageal Reflux Disease
    • 2.1.12.1. EndoStim
  • 2.1.13. Gastroparesis
    • 2.1.13.1. Medtronic
  • 2.1.14. Hearing Loss
    • 2.1.14.1. Advanced Bionics AG/Sonova Group
    • 2.1.14.2. Cochlear, Ltd.
    • 2.1.14.3. MED-EL
  • 2.1.15. Incontinence
    • 2.1.15.1. Medtronic
    • 2.1.15.2. Advanced Uro-Solutions/Medtronic
    • 2.1.15.3. Bioness, Inc.
    • 2.1.15.4. Cogentix Medical (Uroplasty/Vision-Sciences)
  • 2.1.16. Obesity
    • 2.1.16.1. EnteroMedics
    • 2.1.16.2. MetaCure
  • 2.1.17. Obsessive-Compulsive Disorder
    • 2.1.17.1. Medtronic
  • 2.1.18. Sleep Apnea
    • 2.1.18.1. ImThera Medical
    • 2.1.18.2. Inspire Medical Systems
    • 2.1.18.3. Respicardia
    • 2.1.18.4. Others
  • 2.1.19. Spinal Cord Injury/Paralysis
    • 2.1.19.1. BrainGate Research Team
    • 2.1.19.2. Synapse Biomedical
  • 2.1.20. Stroke
    • 2.1.20.1. MicroTransponder
  • 2.1.21. Tinnitus
    • 2.1.21.1. Brainsway
    • 2.1.21.2. Medtronic
    • 2.1.21.3. MicroTransponder
  • Exhibit 2-1: Functional Neuromodulation's DBS-f Technology and Early Clinical Results
  • Exhibit 2-2: NeuroSigma's Monarch eTNS system
  • Exhibit 2-3: MagVenture's MagPro100x System Utilized in Repetitive Transcranial Magnetic Stimulation
  • Exhibit 2-4: Bionic Vision Australia's Retinal Stimulation Technology
  • Exhibit 2-5: Pixium Vision's Bio-Mimetic Camera
  • Exhibit 2-6: Retina Implant's Subretinal Implant Technology
  • Exhibit 2-7: Second Sight Medical Product's Argus II Retinal Prosthesis System
  • Exhibit 2-8: The Fisher Wallace Stimulator
  • Exhibit 2-9: MagVenture's MagVita TMS Therapy system for the Treatment of Depression
  • Exhibit 2-10: Neuronetic's NeuroStar TMS Therapy System for the. Treatment of Depression
  • Exhibit 2-11: BioControl Medical's CardioFit Stimulator
  • Exhibit 2-12: Autonomic Technologies' ATI Neurostimulation System
  • Exhibit 2-13: ElectroCore's Self-Administered gammaCore nVNS System for Treatment of Chronic Cluster Headache and Migraine
  • Exhibit 2-14: Boston Scientific's Precision Spectra SCS System
  • Exhibit 2-15: Medtronic's RestoreSensor with SureScan MRI Technology for the Treatment of Chronic Pain
  • Exhibit 2-16: St. Jude Medical's New Prodigy System with Burst Technology for Improved Pain Management
  • Exhibit 2-17: St. Jude Medical's Eon Neurostimulators for the Treatment of Chronic Pain
  • Exhibit 2-18: St. Jude Medical's Constant Current Circuitry Technology
  • Exhibit 2-19: Clinical Results: a 50% Reduction in Back and Leg Pain after. 2 Years in Patients Receiving St. Jude Medical's Rechargeable Eon Neurostimulator
  • Exhibit 2-20: Neurotherm's Radiofrequency Ablation Technology Application to the Facet Joint in the Spine
  • Exhibit 2-21: NeuroMetrix's SENSUS Pain Management System for the Treatment of Chronic Intractable Pain
  • Exhibit 2-22: Neuros Medical's Altius System High Frequency Nerve Block Technology for the Treatment of Chronic, Peripheral Pain
  • Exhibit 2-23: Nevro's Senza SCS System
  • Exhibit 2-24: SPR Therapeutic's Smartpatch PNS System for the Treatment of. Chronic Shoulder Pain
  • Exhibit 2-25: Stimwave Technologies' FREEDOM SCS System Wireless Pain Relief Technology
  • Exhibit 2-26: Medtronic's Activa Neurostimulator for the Treatment of Parkinson's Disease and Essential Tremor
  • Exhibit 2-27: Cerbomed's Noninvasive NEMOS t-VNS Device for Treatment of Refractory Epilepsy
  • Exhibit 2-28: Cyberonic's/Sorin Group's VNS Therapy System for the Treatment of Epilepsy
  • Exhibit 2-29: NeuroPace's RNS/Responsive Neurostimulation for the Suppression of Epileptic Seizures
  • Exhibit 2-30: NeuroVista/Cyberonic's Seizure Advisory System for the Prediction of Epileptic Seizures
  • Exhibit 2-31: Bioness' L300 Foot Drop FES System
  • Exhibit 2-32: The Enterra II Gastric Neurostimulator for the Treatment. of Gastroparesis
  • Exhibit 2-33: Advanced Bionic's HiRes 90K Implant System for the Treatment of Hearing Loss
  • Exhibit 2-34: Cochlear Ltd.'s Nucleus 6 Sound Processor and Function of Cochlear Implant System
  • Exhibit 2-35: MED-EL's MAESTRO and SYNCHRONY Cochlear Implant Systems
  • Exhibit 2-36: Medtronic's InterStim Therapy System for the Treatment of Incontinence
  • Exhibit 2-37: Cogentix Medical's Urgent PC System for the Treatment of Overactive Bladder
  • Exhibit 2-38: EnteroMedics' Maestro System
  • Exhibit 2-39: Overview of EnteroMedics' VBLOC Therapy. and Vagus Nerve Function
  • Exhibit 2-40: Potential Benefits and Risks of VBLOC Therapy
  • Exhibit 2-41: Comparison of VBLOC Therapy, Laparoscopic Banding,. and Gastric Bypass
  • Exhibit 2-42: MetaCure's DIAMOND (TANTALUS) Gastric Stimulation System
  • Exhibit 2-43: The aura6000 System for the Treatment of Obstructive. Sleep Apnea
  • Exhibit 2-44: Inspire Medical System's Inspire II System for the Treatment of Obstructive Sleep Apnea
  • Exhibit 2-45: An Illustration of Normal and Abnormal Breathing Patterns. in Patients with Central Sleep Apnea
  • Exhibit 2-46: Synapse Biomedical's NeuRx Diaphragm Pacing System
  • Exhibit 2-47: MicroTransponder's Serenity System for the Treatment of Tinnitus

3. IMPLANTABLE NEUROSTIMULATION DEVICES MARKET

  • 3.1. Market Forecast
  • 3.2. Competitive Analysis
    • 3.2.1. Market Share
      • 3.2.1.1. Medtronic plc
      • 3.2.1.2. Boston Scientific
      • 3.2.1.3. St. Jude Medical
      • 3.2.1.4. Cyberonics/Sorin Group
  • 3.3. Emerging Neurostimulation Technologies
    • 3.3.1. Nevro Corp.
    • 3.3.2. Stimwave
    • 3.3.3. Peripheral Nerve Stimulation
      • 3.3.3.1. Bioness
      • 3.3.3.2. Autonomic Technologies, Inc.
  • Exhibit 3-1: Selected Market Drivers and Limiters for Implantable Neurostimulation Devices
  • Exhibit 3-2: Implantable Neurostimulation Devices, Combined Market Forecast, 2014-2019
  • Exhibit 3-3: 2014, Implantable Neurostimulation Devices Market,. Estimated Percentage of Sales, by Type of Therapy
  • Exhibit 3-4: U.S. Neurostimulation Devices Market Forecast, by Therapy Segment, 2014-2019
  • Exhibit 3-5: 2015, Leading Competitors and Products in the Implantable Neurostimulation Devices Market
  • Exhibit 3-6: 2015-2019, Next-Generation Implantable Neurostimulation Systems Pending FDA Approval for Core Indications
  • Exhibit 3-7: 2014, Combined Implantable Neurostimulation Devices Market, Share by Supplier
  • Exhibit 3-8: 2014, Implantable Neurostimulation Devices Market. (DBS/GNS/SCS/SNS/VNS Market, Excluding Cochlear & Retinal Implants), Share by Supplier
  • Exhibit 3-9: 2014, Implantable SCS Devices Market, Share by Supplier
  • Exhibit 3-10: 2014, Cochlear Implants Market, Share by Supplier
  • Exhibit 3-11: Selected Recently FDA-Approved (Implantable/External) Neurostimulation Devices, 2013-2015
  • Exhibit 3-12: Selected Implantable Neurostimulation Devices Expected to Launch in 2015-2016
  • Exhibit 3-13: Selected (Implantable/External) Neurostimulation Devices Expected to Launch in 2017-2019

APPENDIX A: COMPANY LISTING

APPENDIX B: BIBLIOGRAPHY

Back to Top